BioCentury | Dec 12, 2011
Emerging Company Profile

Sera Prognostics: Predicting preemies

Sera Prognostics Inc. is developing a molecular test that it thinks will accurately predict more than 90% of women at risk for preterm birth, allowing earlier monitoring and preventive treatment. The company raised $19.3 million...
BC Week In Review | Aug 23, 2004
Company News

Ciphergen other research news

Researchers published in Cancer Research that a pattern of 3 biomarkers detected stage I/II ovarian cancer with 74% sensitivity at 97% specificity in serum samples from 503 women with ovarian cancer, benign pelvic disease or...
Items per page:
1 - 2 of 2